Medical Innovation, Human Capital Productivity, and the Cross Section of Stock Returns

64 Pages Posted: 1 Sep 2017 Last revised: 28 May 2021

Date Written: May 28, 2021

Abstract

Medical innovation enhances labor health, promotes human capital productivity, and influences asset prices. Using a manually collected dataset on drug approvals to identify medical innovation, I first confirm its direct impact on human capital -- a higher medical innovation shock predicts a higher growth of hours worked and total factor productivity, and firms with higher MedBeta, which is the comovement of stock returns with medical shocks, have significantly higher measures of human capital intensity. Portfolio sorting analyses then suggest that the annual return spread of MedBeta is about 4%. Additional tests confirm medical shock as a positively-priced systemic risk.

Keywords: Medical Innovation, Drug Approval, Systematic Risk, Human Capital

JEL Classification: E23, G12, I15, J24, O33

Suggested Citation

Zhou, Tong, Medical Innovation, Human Capital Productivity, and the Cross Section of Stock Returns (May 28, 2021). Available at SSRN: https://ssrn.com/abstract=3029931 or http://dx.doi.org/10.2139/ssrn.3029931

Tong Zhou (Contact Author)

ShanghaiTech University ( email )

393 Middle Huaxia Road, Pudong
Shanghai, Shanghai 201210
China

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
127
Abstract Views
687
rank
272,187
PlumX Metrics